Conversely, compared to patients with other demyelinating disorders, including neuromyelitis spectrum disorder (NMOSD) and myelin oligodendrocytes glycoprotein-antibody disease (MOGAD), MS patients exhibit a stronger antibody response to pHERV-W and syncytin-1 (28). Here, ERVW-1 is linked to myeloid sarcoma.